POST Online Media Lite Edition



 

Roche extends offer for Spark until November 25

Christian Fernsby |
Roche said it extended its tender offer for shares of Spark Therapeutics until Novembber 25 to give the U.S. Federal Trade Commission (FTC) and the UK Competition and Markets Authority (CMA) more time to complete their reviews of the $4.3 billion deal.

Article continues below



Topics: ROCHE    SPARK   

The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC and the CMA, Roche and Spark said in a joint statement on Tuesday.

The UK competition watchdog had launched an inquiry into the pending acquisition earlier this month.


What to read next

Roche enters strategic collaboration with Foundation Medicine
Autodesk announces $100 million 3D investment fund
New Zealand rejects Huawei's first 5G bid citing national security risk